Earlier treatment in adults with high lifetime risk of cardiovascular diseases: What prevention trials are feasible and could change clinical practice? Report of a National Heart, Lung, and Blood Institute (NHLBI) Workshop

Earlier treatment in adults with high lifetime risk of cardiovascular diseases: What prevention trials are feasible and could change clinical practice? Report of a National Heart, Lung, and Blood Institute (NHLBI) Workshop

More than half of U.S. young adults have low ten-year but high lifetime risk of cardiovascular disease (CVD). Improving primary prevention in young adulthood may help reduce persistent CVD disparities and overall CVD morbidity and mortality. The National Heart, Lung, and Blood Institute (NHLBI) conv...

Full description

Bibliographic Details
Main Authors: Ann Marie Navar, Lawrence J. Fine, Walter T. Ambrosius, Arleen Brown, Pamela S. Douglas, Karen Johnson, Amit V. Khera, Donald Lloyd-Jones, Erin D. Michos, Mahasin Mujahid, Daniel Muñoz, Khurram Nasir, Nicole Redmond, Paul M Ridker, Jennifer Robinson, David Schopfer, Deborah F. Tate, Cora E. Lewis
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:American Journal of Preventive Cardiology
Subjects:
Cardiovascular Disease
Young adults
Atherosclerotic cardiovascular disease
Risk assessment
Online Access:http://www.sciencedirect.com/science/article/pii/S2666667722001143

Internet

http://www.sciencedirect.com/science/article/pii/S2666667722001143

Similar Items